G proteins play an important role in signal transduction from cytokine receptors to intracellular effectors via different pathways, eg involving tyrosine kinases. In our previous studies, we demonstrated that mRNA expression of the hematopoiesisspecific G protein ␣-subunit G␣16 is a sensitive marker indicating the appearance of early myeloid and lymphoid progenitors. This study was designed to investigate cytokine effects on hematopoiesis in vivo and in vitro as reflected by G␣16 expression and sensitivity to the hemoregulatory peptide (pEEDCK)2 which harbors a structural homology to the effector domain of G␣16. Investigations on blood samples from lymphoma patients undergoing salvage therapy with different cytokine support showed that monitoring of the expression of G␣16 mRNA which appears to play a role in cytokine signalling via tyrosine kinases was a valuable complementation to CD34 screening for analyzing hematopoietic recovery after chemotherapy. We demonstrated that in contrast to CD34 which is only expressed in quiescent cells, G␣16 transcription occurs independently of cell cycle state. In vitro, we could show that G␣16 was also a valuable marker for confirming the immature state of ex vivo expanded blood stem cells from patients. A further part of the study was focused on the response of G␣16 and CD34 expressing cells to the granulocyte-derived hemoregulatory peptide (pyroGlu-Glu-Asp-Cys-Lys)2 = (pEEDCK)2 which harbors a G␣16-homologous sequence motif. Results obtained from in vitro assays which involved estimation of colony outgrowth from CD34-positive cells showed that the effect of (pEEDCK)2 on CD34 cells enhanced the effect of IL-3 or SCF. These data indicate that G␣16 may co-operate with (pEEDCK)2 in triggering the cytokine response of immature hematopoietic cells.
Introduction
The quantity of hematopoietic stem cells is generally assessed by determination of their CD34 antigen expression.
1 CD34-positive cells express G␣16 mRNA which has a homology to the Gq class of G protein alpha subunits and was found to be exclusively expressed in hematopoietic cell lines and primary hematopoietic cells. [2] [3] [4] [5] Such Gq-protein ␣-subunits have been recently shown to directly stimulate the activity of a purified non-receptor tyrosine kinase. 6 Involvement in different signal transduction pathways has been proposed. [7] [8] [9] [10] [11] While normal mononuclear cells (MNC) of steady-state hematopoiesis are negative for G␣16 expression, G␣16
Correspondence: M Pfeilstö cker, 3rd Med. Dept. Hanusch Hospital, Heinrich Collin Straße 30, A-1140 Vienna, Austria; Fax: 431/91021/2287 5 Present address: Department of Radiation Therapy and Radiation Biology, Vienna University, Vienna, Austria Received 27 April 1998; accepted 4 January 1999 appears in MNC of patients primed for peripheral blood stem cell (PBSC) harvest and can be detected in purified stem cells with stringent correlation to CD34. 12 The observation that G␣16 has been found in primary myeloid leukemia blasts as well as leukemic cell lines at levels higher than those found in normal CD34 cells further indicates that this group of Gprotein ␣-subunits -like tyrosine kinases -belongs to a group of critical signal transducers whose malfunction is often associated with cancer. In contrast to CD34, G␣16 is expressed in most leukemic cells. 2 The activity of G␣16 mRNA decreases sharply during granulocytic and erythroid differentiation. 3 Within its effector domain, it harbors a sequence homology to the hemoregulatory peptide pEEDCK 12 which in its monomeric form arrests hematopoietic cells at the GI/S transition. 13 pEEDCK has repeatedly been shown to be an efficient stem cell protector during chemotherapy and can also facilitate recovery from radioimmunotherapy. 14, 15 Oxidation of pEEDCK to the disulfide provides a mechanism by which the inhibitor concentration in the body can be reduced. This redox reaction may play a role in the basic regulation of different types of hematopoietic progenitors. 16 It has been repeatedly postulated that the activity of the dimeric form of the granulocyte-derived hemoregulatory peptide pEEDCK is closely associated with stroma-derived cytokines. 17 Synergistic effects which provide the basis for such mechanisms are rather common within the regulation of the cytokine network. A multitude of stimulatory growth factors have been identified which act on hematopoietic cells, whose efficiency is also managed by internal signal transduction mechanisms within the target cells.
In this study, we used stroma-free cultures of CD34-positive cells for testing the effect of (pEEDCK)2 in relation to or in combination with IL-11, IL-6, IL-3 and SCF (stem cell factor = c-kit ligand). In order to elucidate cell cycle effects on G␣16 expression, we synchronized cells by elutriation for further RT-PCR analysis. Additional studies were performed to monitor cytokine effects on G␣16 expression during hematopoietic recovery of lymphoma patients.
Patients and methods

Patients
For expansion cultures, CD34-positive cells were obtained by FACS enrichment from MNC of breast cancer patients who were primed for peripheral stem cell pheresis. For analysis of cytokine effects on G␣16 in vivo, three lymphoma patients undergoing salvage therapy were monitored after chemotherapy and during treatment with different cytokines.
Analysis of G␣16 and CD34 mRNA expression
Peripheral blood samples of patients were collected, subjected to Ficoll separation and used either directly or after cultivation in expansion cultures. For cell cycle experiments, elutriated cells from the KG1 cell line were used. G␣16 mRNA was assessed after mRNA isolation by two-step RT-PCR as previously described. 2 As a negative control, patient-derived genomic DNA (gDNA) was used in order to ensure that our PCR conditions did not favor unspecific amplifications from slight gDNA impurities in our cDNA preparations which might cross-react with our primers. We were aware of a very low risk of primer cross-reaction with pseudogenes, 18, 19 but actin (300 bp fragment from ␤-actin, commercially available from Clontech, Palo Alto, CA, USA) had to be preferred to other genes such as c-abl because of its high steady-state expression which was at a similar level to the expression of G␣16.
Analysis of CD34 antigen expression
CD34 surface antigen expression was determined on a FACS scan using HPAC-2 (Becton Dickinson, Heidelberg, Germany) according to standard procedures.
Monitoring of hematopoietic recovery
Blood counts were performed as part of our routine program. Hematopoietic recovery was considered at a value of WBC Ͼ 1000/mm 3 , platelets Ͼ50 000/mm 3 and reticulocytes Ͼ3‰.
Cell culture of KG1 cells
Before elutriation, KG1 cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum and antibiotics (30 mg/l penicillin, 50 mg/l streptomycin sulfate). The cells were maintained at 37°C, 5% CO 2 and routinely screened for the absence of mycoplasma.
Centrifugal elutriation and evaluation of cell cycle state
Cells were fractionated with a JE-6B Elutriator in a J2-21M centrifuge (Beckmann, Palo Alto, CA, USA) as previously described. 20 Medium flow was controlled with a Cole-Palmer (Chicago, IL, USA) Masterflex pump and the rotor was kept at a speed of 2000 r.p.m., the temperature was 20°C. The elutriation medium was phosphate-buffered saline supplemented with 0.9 mmol/l CaCl 2 , 0.5 mmol/l MgCl 2 and 2% calf serum. Consecutive fractions of 150-200 ml were collected at increasing flow rates. Cell cycle distribution was determined using a PAS III flow cytometer (Partec, Muenster, Germany) after staining of DNA with 6 mol/l 4,6-diamidino-2-phenylindol-dihydrochloride (DAPI).
Synthesis of hemoregulatory peptide
The hemoregulatory peptide monomer and dimer were synthesized, purified and stored as described. 21 The procedure of synthesis started with the monomer, which according to this technique was obtained as the oxidation-resistant, biologically inactive, mixed disulfide of pEEDCK and tertiary butyl mercaptane (S-butyl-sulfenyl-pEEDCK). The pEEDCK monomer was activated immediately before use in the following way: 10 g S-tert.butyl-sulfenyl-pEEDCK was dissolved in 10 l water and added to a solution of 100 g dithioerythritol (DTE) in 10 l 0.5 mol/l triethylamine in 20% aqueous methanol. After incubation at 37°C for 30 min, the solvent and butylmercaptane were removed in vacuo. The residue was dissolved at the desired concentration in RPMI-1640 containing 10 m CaNa 2 EDTA (Serva, Heidelberg, Germany).
The dimer (pEEDCK)2 was synthesized as described previously by oxidation of S-acetamido-methyl-pEEDCK with iodine 21 using the acetamidomethyl group for thiol protection during solid phase synthesis. The product was purified by anion exchange chromatography with the acetamidomethyl group still attached to the cysteine side chain. Excess iodine was removed by gel filtration of Sephadex G-10 (Pharmacia, Uppsala, Sweden).
Expansion cultures and colony assays
For testing the effect of (pEEDCK)2 in comparison to cytokines, assays were established from 30 000 CD34
+ cells which were grown in 300 l RPMI-1640 + Glutamax I, supplemented with 20% FCS and antibiotics. Peptides were added to the cultures every second day. In addition, five purified human recombinant growth factors (rhIL-3, rhIL-6, rhIL-11, rh-SCF and rh-GM-CSF) were used at a concentration of 10 ng/ml culture and added every second day.
At days of culture collection, all cells of one well were collected, counted and 7500 cells from each well were used for colony assay.
For colony assays, expansion cultures on indicated days were resuspended in media composed of RPMI 1640 + Glutamax I, supplemented with 20% FCS and methylcellulose (0.8%, 4000 c.p.s.; Colorcon, Kö nigstein, Germany). Colony formation was induced by rhIL-3 and rh-GM-CSF, each 10 ng/ml). Duplicates from each well were incubated at 37°C in a humidified atmosphere of 7.5% CO 2 in air. After 14 days, aggregates of 50 or more cells were considered colonies.
Statistical analysis
The significance of differences in mean values was determined using the two-tailed Student's t-test, P Ͻ 0.05 was regarded as significant.
Results and discussion
In order to demonstrate effects of chemotherapy and cytokine administration on G␣16 mRNA and CD34 antigen expression in vivo blood counts of lymphoma patients recovering from cytopenia after salvage therapy without cytokines or after G-CSF or IL-3 application were correlated with these markers. In all patients expression of G␣16 could be detected before the onset of hematopoetic recovery as represented by the rise of WBC above 1000/mm 3 ; results for increase of platelets and reticulocytes were similar. Onset of G␣16 demonstrated by RT-PCR always preceded an increase of CD34 antigen to a value of Ͼ1% of MNC, irrespective of cytokine administration (Table 1) . These data confirm the rise of G␣16 during engraftment after autologous stem cell reinfusion 22 and during stem cell mobilisation. 13 Effects of cytokines are reflected by a specific duration of G␣16 expression after administration of different cytokines (data not shown).
As G␣16 appears to be a valuable tool for monitoring cytokine effects we investigated the possible influence of cell cycle on this G protein. Because G␣16 was present both in pEEDCK-inhibited and in normally/logarithmic growing KG1 cells an expression independent of cell cycle state was supposed. 2 For a more specific characterization of cell cycle state we performed elutriation experiments with KG1 cells (Table  2) . While all three fractions expressed G␣16, CD34 mRNA was only detected in the fraction which contained 90% G1/G0 cells (Table 2 ). CD34 data confirm previous reports showing that CD34 mRNA can only be detected in G0 cells (eg, Ref. 23 ).
CD34 cells are also the target of the hemoregulatory peptide (pEEDCK)2, which harbors a sequence homology to the effector domain of G␣16. 12 For testing the effect of this peptide on the growth of CD34 cells in comparison to cytokines, peptide was added every second day to expansion cultures; in addition, four purified human recombinant growth factors (rhIL-3, rhIL-6, rhIL-11, rh-SCF) were used, either as a single additive or in combination with (pEEDCK)2. On indicated days, aliquots from the expansion cultures were seeded in methylcellulose and cultivated without further treatment for CFU-determination.
As seen in Figure 1a and b, growth stimulation using either (pEEDCK)2, IL-11 or IL-6 or a combination of any of these cytokines with the peptide dimer (designated as Di in the figures) reached a maximum of 200 colonies. A combination of each of these cytokines with the dimer displayed significant differences of CFU-output only on day 3 for IL-6 vs IL-6/Di and day 4 for IL-11 vs IL-11/Di.
On the other hand, Figure 1c and d show an up to 5-fold growth stimulation by addition of IL-3 or SCF. A synergistic effect on CFU-formation was achieved by combined application of dimer and each of these cytokines: differences between IL-3 and IL-3/Di were significant on days 1, 3, 4, 5 and 10. Figure 2 presents a comparison of cell count ( Figure 2a ) and colony outgrowth (Figure 2b ) from expansion cultures on days 4 as a detailed example of the supportive effect of (pEEDCK)2. Here we show that cultures containing a similar or even lower cell count (as seen for IL-11 and SCF in Figure 2a ) had a higher rate of colony-forming cells when pre-treated with (pEEDCK)2, which is illustrated by significant differences between IL-11/IL-11+(pEEDCK)2, IL-3/IL-3+(pEEDCK)2 and SCF/SCF+ (pEEDCK)2 (Figure 2b) . A series of RT-PCR assays from expansion cultures confirmed that G␣16 was expressed in all samples, independent of cytokine treatment (data not shown). The higher rate of CFU progenitors in (pEEDCK)2-treated cultures indicates a conserving property of the peptide which antagonizes an evolution of cells towards differentiation.
An activating effect in the growth behavior of (pEEDCK)2-treated or untreated cultures could be observed (Figures 1 and  2 ). Thus, it appears possible that (pEEDCK)2 has the potential to mimic the effect of IL-11 or IL-6 in supporting the growth of CD34-positive cells and to synergize with SCF or IL-3 in a similar way as it is known from, for example, IL-11. 24 As these cytokines occur naturally in the bone marrow, this explains the higher stimulatory activity of (pEEDCK)2 in LTBMCs and in vivo. 25, 26 G protein-mediated cytokine effects are generally known. Therefore, evaluation of G␣16 during cytokine administration in vivo and in vitro is important. A direct interaction of a tyrosine kinase with Gq-protein ␣-subunits from the same class as G␣16 6 has been reported, thus a direct interaction of G␣16 with receptor tyrosine kinases appears possible. Another advantage for the use of G␣16 relies on its cell-type specificity as it is exclusively expressed on hematopoietic cells. (pEEDCK)2 which is structurally related to the effector domain of G␣16 is also highly specific to hematopoietic cells.
We have shown the growth-supporting effect of the hemoregulatory peptide dimer (pEEDCK)2 to primary patient-
Figure 2
Cell count within different expansion cultures after a 5 day incubation with IL-11, IL-6, IL-3 and SCF in the presence or absence of (pEEDCK)2 (a) and efficiency of colony formation of cells derived from these cultures (b). derived CD34-positive cells. It has the property to conserve the immature state of cells. Our results from comparative experiments with cytokines such as IL-11, IL-6, IL-3 and SCF indicate that the effect of (pEEDCK)2 may result from interaction of the peptide with factors produced by the microenvironment. However, the mechanism of how the peptide preserves the cells in their specific immature state or prevents a development towards further differentiation will be the subject of further studies.
Immature hematopoiesis is positive for CD34 and G␣16. An expansion of this cell pool in the bone marrow which is reflected by the appearance of G␣16 in peripheral blood after administration of cytokines in vivo may be related to the presence of endogenous peptide. G␣16 is also of a high value for monitoring hematopoietic recovery after post-therapy cytokine treatment and for characterizing effects of cytokines on hematopoiesis.
Our observation showing that (pEEDCK)2 enhanced the effect of IL-3 or SCF may result from the sequence homology of this peptide with G␣16. These data suggest a functional role of (pEEDCK)2 in signal transduction of hematopoietic cells in connection with G␣16.
